Lindsay Berry

Lindsay Berry

PhD Statistician. Designer of innovative clinical trials. Lover of dogs.

Publications

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Published in New England Journal of Medicine, 2021

In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis.

Recommended citation: The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. NEJM. Published online August 04, 2021. doi:10.1056/NEJMoa2103417 https://www.nejm.org/doi/full/10.1056/NEJMoa2103417

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Published in New England Journal of Medicine, 2021

In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis..

Recommended citation: The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. NEJM. Published online August 04, 2021. doi:10.1056/NEJMoa2105911 https://www.nejm.org/doi/full/10.1056/NEJMoa2105911

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

Published in Intensive Care Medicine, 2021

Results from the REMAP-CAP trial: Among critically ill patients with COVID-19, lopinavir-ritonavir, hydroxychloroquine, or combination therapy worsened outcomes compared to no antiviral therapy.

Recommended citation: Arabi, Y.M., Gordon, A.C., Derde, L.P.G. et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med 47, 867–886 (2021). https://link.springer.com/article/10.1007/s00134-021-06448-5

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

Published in Journal of the American Medical Association, 2021

Meta-analysis estimating the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.

Recommended citation: The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. Published online July 06, 2021. doi:10.1001/jama.2021.11330 https://jamanetwork.com/journals/jama/fullarticle/2781880

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

Published in Trials, 2021

Summary of a study of comparative effectiveness of COVID-19 monoclonal antibodies with FDA EUA in the UPMC Health System.

Recommended citation: Huang, D.T., McCreary, E.K., Bariola, J.R. et al. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. Trials 22, 363 (2021). https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05316-3

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Published in JAMA, 2020

The first results of the REMAP-CAP study reported in JAMA on corticosteroid use for COVID-19.

Recommended citation: The Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324(13):1317–1329. doi:10.1001/jama.2020.17022 https://jamanetwork.com/journals/jama/fullarticle/2770278

Probabilistic forecasting of heterogeneous consumer transaction-sales time series

Published in International Journal of Forecasting, 2020

This paper proposes the dynamic binary cascade model (DBCM) and an extension of the DCMM to forecast transaction-sales time series in consumer sales forecasting contexts.

Recommended citation: Berry, L.R., Helman, P., West, M. "Probabilistic forecasting of heterogeneous consumer transaction-sales time series." 2020. International Journal of Forecasting. https://www.sciencedirect.com/science/article/abs/pii/S0169207019302055

Line-of-sight pursuit in monotone and scallop polygons

Published in International Journal of Computational Geometry & Applications, 2015

This paper was the result of a 2012 Math REU jointly run by Macalester College and the Institute for Mathematics and its Applications at the University of Minnesota.

Recommended citation: Berry, L., Beveridge, A., Butterfield, J., Isler, I., Keller, Z., Shine, A., Wang, J. "Line-of-site pursuit in monotone and scallop polygons." 2019. International Journal of Computational Geometry & Applications. 29(4): 307-351. https://www.worldscientific.com/doi/abs/10.1142/S0218195919500122